Previous 10 | Next 10 |
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences being held virtually: Evercore ISI 4 th Annual HealthCONx Conference on Tuesday, November 30, 20...
Electric vehicle companies remained prominent in Monday's midday trading. Tesla (NASDAQ:TSLA) gained ground on an update of its Model S Plaid launch in China, while Rivian (NASDAQ:RIVN) plunged on news that a joint project with Ford (NYSE:F) has been canceled. Elsewhere, Alnylam Pharmaceutica...
Shares of Alnylam Pharmaceuticals (ALNY +7.0%) are up in trading today following upgrades from Goldman Sachs and RBC Capital Markets. Goldman upgraded the stock to buy from neutral and set a $273 price target (~51% upside). RBC upgraded to outperform with a $225 price target (~24% upside). Go...
Alnylam Pharmaceuticals (NASDAQ:ALNY) says it plans to launch vutrisiran for hATTR amyloidosis in the U.S. early next year following anticipated FDA approval. The biotech anticipates approval of the drug in Europe in mid-2022. Alnylam will begin a phase 3 study of the drug in Stargardt D...
− Introduces New Near-Term Opportunity for Vutrisiran in Stargardt Disease, Expected to Enter Phase 3 Development in Late 2022 – – Adds New Preclinical Cardiovascular Disease Programs, GEMINI-CVR and “Gene X,” with Highly Transfor...
Novo Nordisk paid $3.3 billion to acquire RNAi drug maker Dicerna Pharmaceuticals. Acquisition of Dicerna makes sense from a business standpoint as Novo's strength lies in the metabolic disorder space, especially with key drugs like Ozempic, Wegovy and Saxenda. RNA interference is...
Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis as investor push for the drugmaker to make an acquisition. Alnylam, with a market cap of more than $20B could be a possible acquisition candidate, according to a Bloomberg report, which cited people familiar. Novarti...
Novo Nordisk (NYSE:NVO) has signed an agreement with Dicerna Pharmaceuticals (NASDAQ:DRNA) under which it will acquire Dicerna for $38.25 per share in cash. The purchase consideration indicating a premium of 80% to Dicerna’s closing price on Nov. 17 implies a total equity value of $3.3...
– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing – – Blood Pressure Response to Low-Salt Intake under the Peak P...
Alnylam Pharmaceuticals (NASDAQ:ALNY) announces the initiation of a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known as ALN-AGT), which is being developed as a treatment for hypertension. The trial will evaluate the efficacy and safety of zilebesira...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...